ICLR vs. JAZZ: ICON vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

ICON (ICLR) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both ICON (ICLR) at 4.70% and Jazz Pharmaceuticals (JAZZ) at 5.05% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

ICON (ICLR) at 5.26% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.

Jazz Pharmaceuticals (JAZZ) at 30.17% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both ICON (ICLR) at 0.76% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both ICON (ICLR) at -71.56% and Jazz Pharmaceuticals (JAZZ) at -167.51% post bottom-quartile EPS growth versus peers, pointing to weaker earnings momentum than typical rivals.

Growth Metrics

Financial Strength

Both ICON (ICLR) at 1.32 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither ICON (ICLR) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither ICON (ICLR) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both ICON (ICLR) at 81.90 and Jazz Pharmaceuticals (JAZZ) at 69.46 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while Jazz Pharmaceuticals (JAZZ) at 3.59 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics